Evidence map›Paper›PMID 29806003›Full record

ArticleACS central science2018

Overcoming Ovarian Cancer Drug Resistance with a Cold Responsive Nanomaterial.

Hai Wang, Pranay Agarwal, Gang Zhao, Guang Ji, Christopher M Jewell, John P Fisher, Xiongbin Lu, Xiaoming He

RetractedErratum issuedOpen access · diamondAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS central science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 58 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Ice Inhibition for Cryopreservation: Materials, Strategies, and Challenges.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
    Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 2 countries.

Hai WangFischell Department of Bioengineering and Robert E. Fischell Institute for Biomedical Devices, University of Maryland, College Park, Maryland 20742, United States.
Pranay AgarwalDepartment of Biomedical Engineering and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, United States.
Gang ZhaoCenter for Biomedical Engineering, Department of Electronic Science and Technology, University of Science and Technology of China, Hefei, Anhui 230027, China.
Guang JiInstitute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
Christopher M JewellFischell Department of Bioengineering and Robert E. Fischell Institute for Biomedical Devices, University of Maryland, College Park, Maryland 20742, United States.
John P FisherFischell Department of Bioengineering and Robert E. Fischell Institute for Biomedical Devices, University of Maryland, College Park, Maryland 20742, United States.
Xiongbin LuDepartment of Medical and Molecular Genetics and Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana 46202, United States.
Xiaoming HeFischell Department of Bioengineering and Robert E. Fischell Institute for Biomedical Devices, University of Maryland, College Park, Maryland 20742, United States.
The Ohio State University · USUniversity of Maryland, Baltimore · USIndiana University Health · USShanghai University of Traditional Chinese Medicine · CNUniversity of Maryland, College Park · USUniversity of Science and Technology of China · CN

Funding

Nanotechnology enabled targeting of p53 deficiency in human cancerR01CA206366 · NCI · UNIV OF MARYLAND, COLLEGE PARK · PI HE, XIAOMING, LU, XIONGBIN · 2016 to 2020
$1.9M
NCI NIH HHS R01 CA206366
6 · The paper itself

Abstract

Drug resistance due to overexpression of membrane transporters in cancer cells and the existence of cancer stem cells (CSCs) is a major hurdle to effective and safe cancer chemotherapy. Nanoparticles have been explored to overcome cancer drug resistance. However, drug slowly released from nanoparticles can still be efficiently pumped out of drug-resistant cells. Here, a hybrid nanoparticle of phospholipid and polymers is developed to achieve cold-triggered burst release of encapsulated drug. With ice cooling to below ∼12 °C for both burst drug release and reduced membrane transporter activity, binding of the drug with its target in drug-resistant cells is evident, while it is minimal in the cells kept at 37 °C. Moreover, targeted drug delivery with the cold-responsive nanoparticles in combination with ice cooling not only can effectively kill drug-resistant ovarian cancer cells and their CSCs

Identifiers

PMID29806003
PMCPMC5968444
OpenAlexW2800209693

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.